Denali Therapeutics Inc. (DNLI) is currently priced at $20.07, showing a positive price change of 13 cents (0.652%) from the previous close of $19.94. The trading volume stands at $249,693, representing a 14.85% increase compared to the average.
The latest quarterly earnings report for DNLI, announced on Wednesday, February 25th, revealed an earnings per share of -73 cents, slightly better than the consensus estimate of -75 cents.
The company's cash flow indicates a net change in cash of $114.36 million, with free cash flow at -$100 million. Noteworthy is the issuance of common stock amounting to $192.15 million.
DNLI's income statement shows an operating income of -$137.37 million, resulting in a net income of -$128.55 million. The company reported revenue of $zero and operating expenses totaling $134.50 million.
Key financial ratios for DNLI include a quick ratio of 9.16, cash ratio of 2.09, and a debt-equity ratio of 4.17. Notably, the company's price to earnings ratio stands at -5.63, indicating a potential undervaluation.
The balance sheet reflects total assets of $1.14 billion, with significant holdings in short-term investments at $662.55 million and total investments at $763.98 million. DNLI's net debt is reported at -$163 million.
This financial snapshot of Denali Therapeutics Inc. provides insights into its current performance and financial health.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.